Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
← catalyst calendarSponsored by Prokidney (industry) · PROK — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
53actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-27 | actual | When the study began enrolling |
| Primary completion | 2025-05-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-20 | actual | The whole study's end, after follow-up |
| First posted | 2021-08-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Kidney Diseases
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
Intervention
- Biological: Renal Autologous Cell Therapy (REACT) — also filed as rilparencel
Primary outcomes
what the primary-completion date above is the date OFImprovement in renal function progression rate as indicated by the change from pre-injection baseline value in total (acute + chronic) slope of estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009 equation
measured Screening thru month 28
Procedural and investigational product-related treatment-emergent adverse events (TEAEs) obtained through 18 months after the last REACT injection.
measured Screening thru 18 months after the last injection of study drug
Publications
- PMID 41481370 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PROK's whole pipeline · Catalyst calendar · Every registered study · What changed